Engineering the medicines
of tomorrow

Learn how MorphoSys approaches drug development.

Hematological cancers
affect adults and children alike.

MorphoSys is developing several blood cancer programs.

More Info

Antibody drugs have transformed the way
inflammatory and autoimmune diseases are treated today.

MorphoSys is exploring new approaches to continue this success.

More Info

Solid tumors can occur in
several organs of the human body.

MorphoSys and its partners are working on a broad portfolio of new therapies.

More Info

MorphoSys's vision

MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. A leader in the field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of biopharmaceuticals in the biotechnology industry.

learn more about the company

August 01, 2016
Webcast Half-Year Report

Full details

Half-Year Report
2016

SEE OUR Q2 REPORT

MorphoSys
on Twitter

Visit us on Twitter

Latest
news

29/09/2016

MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody...

Read Media Release

19/09/2016

Lanthio Pharma Expands Management Team

Read Media Release

12/09/2016

MorphoSys Appoints Four R&D Experts to its Newly Formed Scientific...

Read Media Release

06/09/2016

MorphoSys Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus...

Read Media Release

03/08/2016

MorphoSys Successfully Completes Safety Run-in of MOR208 in L-MIND...

Read Media Release

01/08/2016

MorphoSys AG Reports Results for the First Six Months of 2016

Read Media Release

04/07/2016

MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in...

Read Media Release

17/06/2016

MorphoSys Reports Publication of Clinical Case Report of a Blood Cancer (...

Read Media Release

06/06/2016

MorphoSys Presents Updated Clinical Data for MOR202 in Multiple Myeloma...

Read Media Release

02/06/2016

MorphoSys AG Reports Outcome of Annual General Meeting 2016

Read Media Release

Therapeutic pipeline

MorphoSys has established one of the broadest pipelines in the biopharmaceutical industry.

Pipeline

Media and investors

MorphoSys is driven by the ambition to create the most valuable pipeline of biopharmaceuticals in the industry.

Media and investors

Partnering opportunities

Collaborations are a main component of our strategy. We are open to discuss deal structures where we can contribute to the development of novel drugs in a significant way.

Partnering opportunities

Drug development capabilities

MorphoSys is dedicated to become a fully integrated biopharmaceutical company including late stage clinical development and marketing/co-promotion of its own drugs.

Drug development capabilities